Rythmodan 100mg Capsules (2011)
Βιβλιογραφική αναφορά
Στοιχεία εκδότη
Εκδότης | SANOFI |
---|---|
Διεύθυνση | 1 Onslow Street, Guildford, Surrey, GU1 4YS, UK |
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Name of the medicinal product
Rythmodan 100mg Capsules.
Qualitative and quantitative composition
Capsule containing Disopyramide 100mg. For excipients, see section 6.1.
Pharmaceutical form
Capsule.
Therapeutic indications
Rythmodan is used in the treatment of cardiac arrhythmias as follows: The prevention and treatment of arrhythmias occurring after myocardial infarction. Maintenance of normal rhythm following electroconversion ...
Posology and method of administration
Route of administration Oral. 300 mg to 800mg daily in divided doses. Children Not recommended as insufficient data available. Elderly A dose reduction due to reduced renal and hepatic function in the ...
Contraindications
Disopyramide is contra–indicated in un–paced second or third degree atrioventricular block; bundle–branch block associated with first–degree atrioventricular block ; unpaced bifasicular block; pre-existing ...
Special warnings and precautions for use
Antiarrhythmic drugs belonging to the class 1c (Vaughan Williams Classification) were included in the Cardiac Arrhythmia Suppression Trial (CAST), a long term multicentre randomised, double blind study ...
Interaction with other medicinal products and other forms of interaction
Combination with other antiarrhythmic drugs: Combinations of antiarrhythmic drugs are not well researched and their effect may be unpredictable. Thus, antiarrhythmic combination should be avoided except ...
Pregnancy and lactation
Pregnancy Although Rythmodan has undergone animal tests for teratogenicity without evidence of any effect on the developing foetus, its safety in human pregnancy has not been established. Rythmodan has ...
Effects on ability to drive and use machines
Some adverse reactions may impair the patients ability to concentrate and react, and hence the ability to drive or operate machinery. (See section 4.8).
Undesirable effects
Cardiac: It is accepted that the arrhythmogenic potential of disopyramide is weak. However, as with all antiarrhythmic drugs, disopyramide may worsen or provoke arrhythmias. This proarrhythmic effect is ...
Overdose
There is no specific antidote for disopyramide. Prostigmine derivatives can be used to treat anticholinergic effects. Symptomatic supportive measures may include: early gastric lavage; administration of ...
Pharmacodynamic properties
Class 1 anti-arrhythmic agent. It decreases membrane responsiveness, prolongs the effective refractory period (ERP) and slows automaticity in cells with augmented automaticity. Effective refractory period ...
Pharmacokinetic properties
Elimination phase of plasma t<sub>1/2</sub>: 5-8 hours. Increased in hepatic impairment, cardiac and hepatic disease. Protein binding: 50 60%. Saturable and concentration dependent. Volume of distribution: ...
Preclinical safety data
Not applicable.
List of excipients
Maize starch Magnesium stearate STA-RX 1500 (pregelatinised starch) Talc Capsule shell: Gelatin Indigo carmine Iron oxide and Titanium dioxide (E171)
Incompatibilities
Not known.
Shelf life
PVC Blister: 36 months.
Special precautions for storage
Do not store above 25°C.
Nature and contents of container
Sanofi-aventis One Onslow Street Guildford Surrey GU1 4YS UK
Nature and contents of container
PVC Blister containing 84 capsules.
Special precautions for disposal and other handling
None.
Marketing authorization number(s)
PL 04425/0607
Date of first authorization / renewal of the authorization
12 February 2009
Date of revision of the text
24 February 2010